- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Iridex launches DME patient education Web site
Iridex Corp. has launched www.treatmydme.com, an educational Web site designed to benefit patients who have diabetic macular edema (DME).
Mountain View, CA-Iridex Corp. has launched www.treatmydme.com, an educational Web site designed to benefit patients who have diabetic macular edema (DME).
The new site explains DME, describes the company’s proprietary technology to treat it (MicroPulse Laser Therapy), and addresses patients’ expectations before, during, and after treatment.
“The Web site’s launch will facilitate increased patient awareness and education on [the technology] as a viable option for the treatment of DME,” said Sam Mansour, MD, MSc, FRCS(C), FACS, medical director of the Virginia Retina Center, Warrenton, and clinical professor of ophthalmology, George Washington University, Washington, DC. “For patients struggling with DME, it’s important to have easy access to information on the disease and treatment options.”
The proprietary technology is a retina-sparing solution for the treatment of DME, according to the company.
For more articles in this issue of Ophthalmology Times eReport, click here.
